Clinical trial

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

NCT03897868

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HCP1803 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Amlodipine Normalized identity: amlodipineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Losartan Normalized identity: losartanView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-03-21

PhasePHASE2

Conditions

Hypertensionunresolved

Interventions

HCP1803DRUG

AmlodipineDRUG · verified · RxNorm: amlodipine

LosartanDRUG · verified · RxNorm: losartan

PlaceboDRUG

Sponsors & collaborators

Hanmi Pharmaceutical Company Limitedlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03897868 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.